

# Luciano Cascione

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4600633/publications.pdf>

Version: 2024-02-01

170  
papers

4,756  
citations

109321

35  
h-index

110387

64  
g-index

179  
all docs

179  
docs citations

179  
times ranked

9215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	1.7	13
2	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
3	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. <i>Frontiers in Endocrinology</i> , 2022, 13, 834075.	3.5	5
4	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers</i> , 2022, 14, 1018.	3.7	7
5	Resistance to PI3KÎ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFR $\alpha$ axis. <i>Haematologica</i> , 2022, 107, 2685-2697.	3.5	10
6	Radiomics Analysis of [ <sup>18</sup> F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment. <i>Thyroid</i> , 2021, 31, 88-95.	4.5	23
7	Exonâ€Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation. <i>Non-coding RNA</i> , 2021, 7, 26.	2.6	3
8	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. <i>Blood Advances</i> , 2021, 5, 2467-2480.	5.2	10
9	RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis. <i>BMC Bioinformatics</i> , 2021, 22, 298.	2.6	7
10	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. <i>Haematologica</i> , 2021, , .	3.5	3
11	Abstract 2373: Expression of exosomal let-7g in biofluids and outcome in colon cancer patient treated with anti-EGFR therapy. , 2021, , .		0
12	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. <i>Cell Death and Differentiation</i> , 2021, 28, 2970-2982.	11.2	13
13	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. <i>Oncology Reports</i> , 2021, 47, .	2.6	8
14	ASB2 is a direct target of FLI1 that sustains NF-ÎB pathway activation in germinal center-derived diffuse large B-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 357.	8.6	7
15	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, 586-601.	0.8	3
16	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020, 33, 179-187.	5.5	37
17	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020, 72, 982-996.	7.3	30
18	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type. <i>Cancers</i> , 2020, 12, 1912.	3.7	4

#	ARTICLE	IF	CITATIONS
19	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. <i>Frontiers in Oncology</i> , 2020, 10, 584095.	2.8	9
20	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. <i>Hematological Oncology</i> , 2020, 38, 831-833.	1.7	1
21	Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. <i>European Journal of Cancer</i> , 2020, 138, S40.	2.8	5
22	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020, 4, 4124-4135.	5.2	37
23	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020, 4, 819-829.	5.2	28
24	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. <i>Hematological Oncology</i> , 2020, 38, 715-725.	1.7	14
25	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. <i>Pathology Research and Practice</i> , 2020, 216, 152907.	2.3	17
26	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	3.5	29
27	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	5.2	47
28	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , 2020, 105, 2584-2591.	3.5	27
29	Abstract 4206: EUD-GK-001 is a novel kinase inhibitor within vitro anti-lymphoma activity. , 2020, , .		0
30	Abstract 163: DNA methyltransferase modulation in lymphoma cells involves functional redundancy and maintains hypermethylation of selected regions. , 2020, , .		0
31	Abstract 5215: Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B cell lymphoma. , 2020, , .		0
32	Abstract 1417: Development of a miRNA-based prediction tool to discriminate cutaneous blastic plasmacytoid dendritic cell neoplasm from cutaneous myeloid sarcoma. , 2020, , .		0
33	Understanding the mechanism of action of pyrrolo[3,2- <i>b</i> ]quinoxaline-derivatives as kinase inhibitors. <i>RSC Medicinal Chemistry</i> , 2020, 11, 665-675.	3.9	4
34	Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity. <i>Blood</i> , 2020, 136, 10-11.	1.4	2
35	Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. , 2020, , .		1
36	Abstract PO-07: The FLI1 direct target ASB2 promotes NF- $\kappa$ B pathway activation in diffuse large B-cell lymphoma of the germinal center B-cell type. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
37	Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. <i>British Journal of Haematology</i> , 2019, 187, 478-487.	2.5	9
38	&lt;p&gt;Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7845-7855.	1.9	6
39	A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. <i>Lecture Notes in Computer Science</i> , 2019, , 24-32.	1.3	0
40	Single and combined BTK and PI3KÎ inhibition with acalabrutinib and ACPâ€319 in preâ€clinical models of aggressive lymphomas. <i>British Journal of Haematology</i> , 2019, 187, 595-601.	2.5	12
41	Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. <i>Annals of Oncology</i> , 2019, 30, iv110-iv111.	1.2	0
42	Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients. <i>Annals of Oncology</i> , 2019, 30, v786.	1.2	0
43	THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 77-77.	1.7	0
44	THE ANTIBODYâ€DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCTâ€402) TARGETING CD19 SHOWS STRONG <i>IN VITRO</i> ANTIâ€LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. <i>Hematological Oncology</i> , 2019, 37, 129-130.	1.7	5
45	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
46	Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. <i>Non-coding RNA</i> , 2019, 5, 47.	2.6	12
47	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. <i>Haematologica</i> , 2019, 104, e307-e309.	3.5	14
48	EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 513-514.	1.7	0
49	COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B- AND T-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2019, 37, 318-319.	1.7	2
50	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , 2019, 11, 775.	3.7	14
51	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. <i>Clinical Cancer Research</i> , 2019, 25, 5167-5176.	7.0	43
52	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	3.5	55
53	Integration of Omics Data to Identify Cancer-Related MicroRNA. <i>Methods in Molecular Biology</i> , 2019, 1970, 85-99.	0.9	0
54	Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. <i>PLoS ONE</i> , 2019, 14, e0215154.	2.5	15

#	ARTICLE	IF	CITATIONS
55	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019, 104, 1633-1639.	3.5	28
56	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	2.5	31
57	Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , 2019, 3, 384-396.	5.2	16
58	THE FIRST-IN-CLASS ETS INHIBITOR TK-216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 322-322.	1.7	0
59	THE ANTI-CD25 ANTIBODY-DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT-301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. <i>Hematological Oncology</i> , 2019, 37, 323-324.	1.7	5
60	EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT. <i>Hematological Oncology</i> , 2019, 37, 179-180.	1.7	3
61	SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). <i>Hematological Oncology</i> , 2019, 37, 512-513.	1.7	0
62	THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). <i>Hematological Oncology</i> , 2019, 37, 75-75.	1.7	0
63	MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 319-319.	1.7	1
64	<i>In vitro</i> demonstration of synergism with pixantrone combined with targeted agents in lymphomas. <i>British Journal of Haematology</i> , 2019, 186, 149-152.	2.5	3
65	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , 2019, 104, e256-e259.	3.5	43
66	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. <i>Blood</i> , 2019, 133, 156-167.	1.4	40
67	MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. <i>Head and Neck Pathology</i> , 2019, 13, 344-354.	2.6	12
68	Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 1022-1025.	2.5	5
69	Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. , 2019, , .		3
70	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569.	1.4	3
71	Early progression of disease (POD24) as survival predictor in MALT lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7548-7548.	1.6	0
72	Abstract 4796: EG-011 is a novel small molecule <i>in vitro</i> and <i>in vivo</i> anti-tumor activity against lymphoma. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract 1805: Integrative analysis of microRNAs in blastic plasmacytoid dendritic cell neoplasm. , 2019, , .		0
74	Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures. , 2019, , .		3
75	Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBBP/EP300 inhibitors in diffuse large B cell lymphoma. , 2019, , .		1
76	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. Blood, 2019, 134, 2858-2858.	1.4	1
77	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). Blood, 2019, 134, 4010-4010.	1.4	1
78	Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents. , 2019, , .		0
79	Abstract 4796: EG-011 is a novel small molecule with <i>in vitro</i> and <i>in vivo</i> anti-tumor activity against lymphoma. , 2019, , .		0
80	Metabolic heterogeneity on baseline 18F-FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 2018, 132, 179-186.	1.4	63
81	Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with standard immunotherapy: A large retrospective study from 4 institutions. Hematological Oncology, 2018, 36, 84-92.	1.7	8
82	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1a/2 study. British Journal of Haematology, 2018, 182, 453-456.	2.5	4
83	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
84	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
85	cuRnet: an R package for graph traversing on GPU. BMC Bioinformatics, 2018, 19, 356.	2.6	4
86	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open, 2018, 3, e000387.	4.5	21
87	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	3.5	13
88	A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. Cancer Research, 2018, 78, 5741-5753.	0.9	28
89	Abstract 4275: Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. , 2018, , .		4
90	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphoma than with Single BET or Crebbp/EP300 Inhibitors. Blood, 2018, 132, 4174-4174.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	1.4	2
92	Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103. <i>Molecular Cancer Therapeutics</i> , 2018, 17, B061-B061.	4.1	2
93	Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity. , 2018, , .		0
94	Abstract 2853: Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMG529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL). , 2018, , .		2
95	Abstract 799: The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent. , 2018, , .		0
96	Abstract 796: The BTK inhibitor BGB-3111 is synergistic with other anti-lymphoma targeted agents. , 2018, , .		0
97	Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma. , 2018, , .		0
98	Abstract 1894: Identification of novel OTX015-containing combinations for lymphoma treatment. , 2018, , .		0
99	New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease. <i>Blood</i> , 2018, 132, 4173-4173.	1.4	0
100	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. <i>Gut</i> , 2017, 66, 1268-1277.	12.1	75
101	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. <i>Scientific Reports</i> , 2017, 7, 3140.	3.3	55
102	Characterisation of the immune-related transcriptome in resected biliary tract cancers. <i>European Journal of Cancer</i> , 2017, 86, 158-165.	2.8	47
103	DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma. <i>Scientific Reports</i> , 2017, 7, 11591.	3.3	29
104	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	1.4	149
105	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	30.7	145
106	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 936-948.	2.5	42
107	Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma. , 2017, , .		0
108	Prognostic value of the immune-related transcriptome in biliary tract cancers. <i>Annals of Oncology</i> , 2016, 27, vi234.	1.2	0



#	ARTICLE	IF	CITATIONS
109	The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. <i>European Journal of Cancer</i> , 2016, 69, S38.	2.8	1
110	HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity. <i>Journal of Hepatology</i> , 2016, 64, S559.	3.7	0
111	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	1.4	147
112	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 115, 1343-1350.	6.4	27
113	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. <i>Annals of Oncology</i> , 2016, 27, 1123-1128.	1.2	26
114	ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2016, 128, 1755-1755.	1.4	1
115	Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMG529. <i>Blood</i> , 2016, 128, 4187-4187.	1.4	6
116	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. <i>Oncotarget</i> , 2016, 7, 58142-58147.	1.8	25
117	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. <i>Oncotarget</i> , 2016, 7, 4915-4924.	1.8	26
118	The genetic landscape of dural marginal zone lymphomas. <i>Oncotarget</i> , 2016, 7, 43052-43061.	1.8	28
119	Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers. , 2016, , .		0
120	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		0
121	P0282 : The long non coding RNA UC.158 modulates growth of Wnt/ $\beta$ -catenin driven hepatocellular carcinoma (HCC). <i>Journal of Hepatology</i> , 2015, 62, S413-S414.	3.7	0
122	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
123	The novel atypical retinoid ST-5589 downregulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. <i>British Journal of Haematology</i> , 2015, 171, 378-386.	2.5	5
124	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. <i>Oncotarget</i> , 2015, 6, 3394-3408.	1.8	56
125	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14924-14929.	7.1	74
126	TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. <i>Cancer Research</i> , 2015, 75, 1908-1921.	0.9	56



#	ARTICLE	IF	CITATIONS
127	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.	7.0	237
128	miR-15b/16-2 deletion promotes B-cell malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11636-11641.	7.1	98
129	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
130	Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models. , 2015, , .		2
131	The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. <i>Blood</i> , 2015, 126, 4005-4005.	1.4	1
132	Gradual Rarefaction of Hematopoietic Precursors and Atrophy in a Depleted microRNA 29a, b and c Environment. <i>PLoS ONE</i> , 2015, 10, e0131981.	2.5	3
133	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of <i>CDKN1A</i> expression levels in mediating their anti-tumor response. <i>Oncotarget</i> , 2015, 6, 5059-5071.	1.8	29
134	A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. <i>Oncotarget</i> , 2015, 6, 20829-20839.	1.8	89
135	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. <i>Oncotarget</i> , 2015, 6, 31134-31150.	1.8	38
136	Abstract 3083: Global gene expression profiling of mice tumor-derived organoids identifies key microRNAs and metabolic genes involved in CRC progression. , 2015, , .		0
137	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, , .		0
138	The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2015, 126, 5119-5119.	1.4	1
139	miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. <i>Nucleic Acids Research</i> , 2014, 42, 5416-5425.	14.5	36
140	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. <i>Cancer Cell</i> , 2014, 25, 469-483.	16.8	267
141	Protective role of miR-155 in breast cancer through <i>RAD51</i> targeting impairs homologous recombination after irradiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4536-4541.	7.1	181
142	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	7.2	55
143	The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3113-3113.	1.4	1
144	BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrnas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4495-4495.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options. PLoS ONE, 2014, 9, e88525.	2.5	79
146	microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget, 2014, 5, 1174-1184.	1.8	136
147	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. Oncotarget, 2014, 5, 1185-1197.	1.8	17
148	Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes. , 2014, , .		0
149	Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response. , 2014, , .		0
150	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0
151	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. Blood, 2014, 124, 3377-3377.	1.4	1
152	Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia, 2013, 27, 740-743.	7.2	18
153	Elucidating the Role of microRNAs in Cancer Through Data Mining Techniques. Advances in Experimental Medicine and Biology, 2013, 774, 291-315.	1.6	6
154	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	8.5	121
155	Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RAR $\beta$ and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9812-9817.	7.1	53
156	A Sleeping Beauty screen reveals NF- $\kappa$ B activation in CLL mouse model. Blood, 2013, 121, 4355-4358.	1.4	31
157	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. Blood, 2013, 122, 1853-1853.	1.4	8
158	Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer. PLoS ONE, 2013, 8, e55910.	2.5	158
159	MIDClass: Microarray Data Classification by Association Rules and Gene Expression Intervals. PLoS ONE, 2013, 8, e69873.	2.5	17
160	Abstract 3061: Micro-RNA signature differences in lung cancer patients withALKtranslocation,EGFRmutations andKRASmutations.. , 2013, , .		0
161	Abstract 1951: miRNA expression profile of Blastic plasmacytoid dendritic cell neoplasm.. , 2013, , .		0
162	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	5.2	0

#	ARTICLE	IF	CITATIONS
163	Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation.. , 2013, , .		0
164	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0
165	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in nonâ€“small-cell lung cancer through BIM down-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16570-16575.	7.1	150
166	miR-EdiTar: a database of predicted A-to-I edited miRNA target sites. Bioinformatics, 2012, 28, 3166-3168.	4.1	28
167	Regulation of acute graft-versus-host disease by microRNA-155. Blood, 2012, 119, 4786-4797.	1.4	128
168	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	1.4	0
169	Recombinant Î±-interferon 2b in the treatment of HIV-related thrombocytopenia. Aids, 1993, 7, 823-828.	2.2	10
170	Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment. Frontiers in Oncology, 0, 12, .	2.8	2